Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
The Journal of Allergy and Clinical Immunology
|
December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Emma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Dermatology and Therapy
|
June 28, 2021
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
Rebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Drug Discovery Today
|
February 22, 2025
Unlocking disease insights to facilitate drug development: Pharmaceutical industry-academia collaborations in inflammation and immunology
Elena Peeva, Emma Guttman-Yassky, Yuji Yamaguchi, et al.
Journal of the American Academy of Dermatology
|
October 26, 2024
A phase 2a trial of brepocitinib for cicatricial alopecia
Eden David, Neda Shokrian, Ester Del Duca, et al.
Eclinicalmedicine
|
March 19, 2026
Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial
Severine Vermeire, Jessica R Allegretti, Hyo Jong Kim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 14, 2021
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
Silvio Danese, Maria Klopocka, Ellen J Scherl, et al.
Arthritis Research & Therapy
|
June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Stanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Journal of the American Academy of Dermatology
|
November 12, 2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, et al.
The Lancet. Gastroenterology & Hepatology
|
July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
Silvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 27, 2013
Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis
Andrew L Rankin, Nilufer Seth, Sean Keegan, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
The Journal of Allergy and Clinical Immunology
|
December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Emma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Dermatology and Therapy
|
June 28, 2021
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
Rebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Drug Discovery Today
|
February 22, 2025
Unlocking disease insights to facilitate drug development: Pharmaceutical industry-academia collaborations in inflammation and immunology
Elena Peeva, Emma Guttman-Yassky, Yuji Yamaguchi, et al.
Journal of the American Academy of Dermatology
|
October 26, 2024
A phase 2a trial of brepocitinib for cicatricial alopecia
Eden David, Neda Shokrian, Ester Del Duca, et al.
Eclinicalmedicine
|
March 19, 2026
Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial
Severine Vermeire, Jessica R Allegretti, Hyo Jong Kim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 14, 2021
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
Silvio Danese, Maria Klopocka, Ellen J Scherl, et al.
Arthritis Research & Therapy
|
June 6, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Stanley Cohen, Jean S Beebe, Vishala Chindalore, et al.
Journal of the American Academy of Dermatology
|
November 12, 2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, et al.
The Lancet. Gastroenterology & Hepatology
|
July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
Silvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 27, 2013
Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis
Andrew L Rankin, Nilufer Seth, Sean Keegan, et al.
Page
of 9